Abstract
To analyze humoral cross-reactivity to V3 peptides from subtype B and BF recombinant forms, plasma samples from 50 HIV-1-infected patients were characterized by sequencing fragments of the env and pol genes. An in-house EIA was performed using peptides corresponding to the 15 central amino acids of the V3 loop of gp120 from subtypes B (MN, SF2) and F1 and a consensus peptide from Argentinean BF recombinants. No differences were found with respect to the infecting subtype, but significant differences were found among the peptides. Reactivity was higher against the MN and BF peptides in both groups infected with subtype B (n = 28) and BF (n = 22) recombinants than against subtype F1 and SF2 peptides.
References
McCutchan FE (2000) Understanding the genetic diversity of HIV-1. AIDS 14(Suppl 3):S31–S44
Sabino EC, Shpaer EG, Morgado MG, Korber BT, Diaz RS et al (1994) Identification of human immunodeficiency virus type 1 envelope genes recombinant between subtypes B and F in two epidemiologically linked individuals from Brazil. J Virol 68:6340–6346
Carr JK, Salminen MO, Koch C, Gotte D, Artenstein AW et al (1996) Full-length sequence and mosaic structure of a human immunodeficiency virus type 1 isolate from Thailand. J Virol 70:5935–5943
Marquina S, Leitner T, Rabinovich RD, Benetucci J, Libonatti O et al (1996) Coexistence of subtypes B, F, and as B/F env recombinant of HIV type 1 in Buenos Aires Argentina. AIDS Res Hum Retroviruses 12:1651–1654
Fernandez-Medina D, Jansson M, Rabinovich RD, Libonatti O, Wigzell H (1999) Identification of human immunodeficiency virus type 1 subtypes B and F B/F recombinant and dual infection with these subtypes in Argentina. Scand J Infect Dis 31:235–242
Comez Carrillo M, Salomon H, Pando MA, Kijak G, Avila MM (2001) Distribution of subtypes and recombinant of HIV. Situation in Argentina. Medicina (B Aires) 61:881–889
Carr JK, Avila M, Gomez Carrillo M, Salomon H, Hierholzer J et al (2001) Diverse BF recombinants have spread widely since the introduction of HIV-1 into South America. AIDS 15:F41–F47
Avila MM, Pando MA, Carrion G, Peralta LM, Salomon H et al (2002) Two HIV-1 epidemics in Argentina: different genetic subtypes associated with different risk groups. J Acquir Immune Defic Syndr 29:422–426
Gomez Carrillo M, Avila M, Hierholzer J, Pando M, Martinez PL et al (2002) Mother-to-child HIV type 1 transmission in Argentina: BF recombinants have predominated in infected children since the mid-1980s. AIDS Res Hum Retroviruses 18:477–483
Turk G, Gherardi MM, Laufer N, Saracco M, Luzzi R et al (2008) Magnitude, breadth, and functional profile of T-cell responses during human immunodeficiency virus primary infection with B and BF viral variants. J Virol 82:2853–2866
Humbert M, Dietrich U (2006) The role of neutralizing antibodies in HIV infection. AIDS Rev 8:51–59
Zolla-Pazner S (2005) Improving on nature: focusing the immune response on the V3 loop. Hum Antibodies 14:69–72
Teixeira SL, Bastos FI, Telles PR, Hacker MA, Brigido LF et al (2004) HIV-1 infection among injection and ex-injection drug users from Rio de Janeiro, Brazil: prevalence, estimated incidence and genetic diversity. J Clin Virol 31:221–226
Eyer-Silva WA, Couto-Fernandez JC, Morgado MG (2007) Molecular epidemiology of HIV type 1 in inner Rio De Janeiro State, Brazil. AIDS Res Hum Retroviruses 23:303–308
Buonaguro L, Tagliamonte M, Tornesello M, Buonaguro FM (2007) Evolution of the HIV-1 V3 region in the Italian epidemic. New Microbiol 30:1–11
Sierra M, Thomson MM, Rios M, Casado G, Castro RO et al (2005) The analysis of near full-length genome sequences of human immunodeficiency virus type 1 BF intersubtype recombinant viruses from Chile, Venezuela and Spain reveals their relationship to diverse lineages of recombinant viruses related to CRF12_BF. Infect Genet Evol 5:209–217
Stanfield RL, Gorny MK, Zolla-Pazner S, Wilson IA (2006) Crystal structures of human immunodeficiency virus type 1 (HIV-1) neutralizing antibody 2219 in complex with three different V3 peptides reveal a new binding mode for HIV-1 cross-reactivity. J Virol 80:6093–6105
Cardozo T, Swetnam J, Pinter A, Krachmarov C, Nadas A et al (2009) Worldwide distribution of HIV type 1 epitopes recognized by human anti-V3 monoclonal antibodies. AIDS Res Hum Retroviruses 25:441–450
Krachmarov C, Pinter A, Honnen WJ, Gorny MK, Nyambi PN et al (2005) Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade a and clade B V3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking. J Virol 79:780–790
Pampuro SE, Calarota SA, Marquina SA, Rabinovich RD, Libonatti OV (1996) Reactivity of Argentine serum samples against synthetic V3-based HIV-1 peptides. J Acquir Immune Defic Syndr Hum Retrovirol 12:527–528
Koch M, Pancera M, Kwong PD, Kolchinsky P, Grundner C et al (2003) Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition. Virology 313:387–400
Teeraputon S, Louisirirojchanakul S, Auewarakul P (2005) N-linked glycosylation in C2 region of HIV-1 envelope reduces sensitivity to neutralizing antibodies. Viral Immunol 18:343–353
Schilling R, Heil A, Langner K, Pohlmeyer K, Larsen M et al (2006) A multivalent HIV-vaccine: development of a plasmid DNA for the expression of HIV envelope glycoproteins with hypervariable V3-loop domains. Vaccine 24:4648–4650
Vaine M, Wang S, Crooks ET, Jiang P, Montefiori DC et al (2008) Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccination. J Virol 82:7369–7378
Eda Y, Takizawa M, Murakami T, Maeda H, Kimachi K et al (2006) Sequential immunization with V3 peptides from primary human immunodeficiency virus type 1 produces cross-neutralizing antibodies against primary isolates with a matching narrow-neutralization sequence motif. J Virol 80:5552–5562
Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J et al (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361:2209–2220
Acknowledgments
Peptides (MN, SF2, F) were obtained through the AIDS Research and Reference Reagent Program, AIDS Program, NIAID, NIH: HIV-1V3 peptides were obtained from the Division of AIDS, NIAID. This work was supported by grants to L.M.P. from the University of Buenos Aires (M043) and the National Agency for Promotion of Science and Technology (PICT 2007-1021).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ambrosioni, J., Andreani, G., Acuipil, C. et al. Comparative reactivity of serum samples from Argentinean HIV-infected patients with V3 peptides from subtype B or BF recombinants. Arch Virol 155, 2029–2034 (2010). https://doi.org/10.1007/s00705-010-0785-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00705-010-0785-y